" " indicates required fields



Highly Accurate Results
Benefit from detailed Device Under Test (DUT) reports for enhanced testing effectiveness, achieving precision in testing outcomes and conclusions.
Unified and Adaptable Views
Dedicated and customizable dashboard provides centralized test management, real-time progress updates, and full transparency into cybersecurity testing throughout the product lifecycle.
Cost and Time Efficiency
Minimize computing costs and testing time in your CI/CD or Target by optimizing testing through intelligent prioritization and feasibility screening.
Flexible Test Execution
Integrate testing into the CI/CD pipelines via APIs or execute ad-hoc activities for one-time campaigns.
Knowledge Sharing and Collaboration
A unified product security platform for all stakeholders, internal and external to the organization.
“Fuzz testing, with C2A Security’s solution, enables early discovery of vulnerabilities hence reducing the time needed to deliver SW and products.”
CRO
C2A Security
VP and GM, Medical Technology
C2A Security
Ken Zalevsky brings over 20 years of medical device cybersecurity experience to his role at C2A Security, where he serves as VP and GM, Medical Technology, following the acquisition of Vigilant Ops in October 2025. A former Bayer executive, Ken founded Vigilant Ops in 2019 after witnessing the consequences of inadequate technical preparation in the healthcare industry. He is an active contributor to CISA’s SBOM working groups and a frequent speaker on software supply chain security. Ken’s mission: transform SBOM from a compliance checkbox into operational intelligence that keeps patients safe while streamlining regulatory processes.